These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30745203)

  • 1. A systematic approach for successful PCSK9 inhibitor prescribing in clinical practice.
    Knickelbine T; Jia L; White SK; Garberich RF; Oberembt SJ; Wills S; Miedema MD; Brilakis ES
    J Clin Lipidol; 2019; 13(2):265-271. PubMed ID: 30745203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.
    Hess GP; Natarajan P; Faridi KF; Fievitz A; Valsdottir L; Yeh RW
    Circulation; 2017 Dec; 136(23):2210-2219. PubMed ID: 29084735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions.
    Doshi JA; Li P; Puckett JT; Pettit AR; Raman S; Parmacek MS; Rader DJ
    Value Health; 2020 Feb; 23(2):209-216. PubMed ID: 32113626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association.
    Cohen JD; Cziraky MJ; Jacobson TA; Maki KC; Karalis DG
    J Clin Lipidol; 2017; 11(4):891-900. PubMed ID: 28550993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.
    Navar AM; Taylor B; Mulder H; Fievitz E; Monda KL; Fievitz A; Maya JF; López JAG; Peterson ED
    JAMA Cardiol; 2017 Nov; 2(11):1217-1225. PubMed ID: 28973087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic.
    Zafrir B; Jubran A
    Cardiovasc Ther; 2018 Oct; 36(5):e12439. PubMed ID: 29863817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates.
    Reynolds VW; Chinn ME; Jolly JA; Kelley TN; Peter ME; Choi L; Nwosu S; Leon BC; Zuckerman AD
    J Clin Lipidol; 2019; 13(2):254-264. PubMed ID: 30745204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes.
    Myers KD; Farboodi N; Mwamburi M; Howard W; Staszak D; Gidding S; Baum SJ; Wilemon K; Rader DJ
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005404. PubMed ID: 31331194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of PCSK9 Inhibitors in Practice.
    Kaufman TM; Warden BA; Minnier J; Miles JR; Duell PB; Purnell JQ; Wojcik C; Fazio S; Shapiro MD
    Circ Res; 2019 Jan; 124(1):32-37. PubMed ID: 30605414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.
    Mallya UG; Boklage SH; Koren A; Delea TE; Mullins CD
    Pharmacoeconomics; 2018 Jan; 36(1):115-126. PubMed ID: 29181773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers.
    Doshi JA; Puckett JT; Parmacek MS; Rader DJ
    Circ Cardiovasc Qual Outcomes; 2018 Jan; 11(1):e003939. PubMed ID: 29326146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom.
    Tai MH; Shepherd J; Bailey H; Williams N; Hatz M; Campos Tapias I; Catterick D; Worth G
    Curr Med Res Opin; 2019 May; 35(5):829-835. PubMed ID: 30289004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
    Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitor Prescriptions for Secondary Prevention of Clinical Atherosclerotic Cardiovascular Disease.
    Blumenthal DM; Maddox TM; Aragam K; Sacks CA; Virani SS; Wasfy JH
    Circ Cardiovasc Qual Outcomes; 2021 Sep; 14(9):e007237. PubMed ID: 34404223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors.
    Rane PB; Patel J; Harrison DJ; Shepherd J; Leith A; Bailey H; Piercy J
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):103-108. PubMed ID: 28849360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
    Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
    JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry.
    Schmidt N; Dressel A; Grammer TB; Gouni-Berthold I; Julius U; Kassner U; Klose G; König C; Koenig W; Otte B; Parhofer KG; Reinhard W; Schatz U; Schunkert H; Steinhagen-Thiessen E; Vogt A; Laufs U; März W
    Atherosclerosis; 2018 Oct; 277():314-322. PubMed ID: 30270065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consensus statement of professional associations on prescribing of PCSK9-inhibitors.
    Češka R; Táborský M; Vrablík M
    Vnitr Lek; 2019; 64(12):1131-1136. PubMed ID: 30704246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.